2024
Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.
Xiang X, Bhowmick K, Shetty K, Ohshiro K, Yang X, Wong L, Yu H, Latham P, Satapathy S, Brennan C, Dima R, Chambwe N, Sharifova G, Cacaj F, John S, Crawford J, Huang H, Dasarathy S, Krainer A, He A, Amdur R, Mishra L. Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis. Genes & Cancer 2024, 15: 1-14. PMID: 38323119, PMCID: PMC10843195, DOI: 10.18632/genesandcancer.234.Peer-Reviewed Original ResearchHepatocellular carcinomaPyruvate kinase M2TGF-bPresence of hepatocellular carcinomaEarly detection of HCCRisk of hepatocellular cancerDetection of hepatocellular carcinomaAdvanced incurable stageRisk-stratifying biomarkersTGF-B pathwayAssociated with hepatocellular carcinomaProteomic markersEarly detectionBiologically relevant markersIncurable stageBlood-based biomarkersHepatocellular cancerRisk stratificationStratify riskNon-HCCClinical variablesBlood levelsLiver diseaseAnimal modelsBiological role
2020
Development of a serum miRNA panel for detection of early stage non-small cell lung cancer
Ying L, Du L, Zou R, Shi L, Zhang N, Jin J, Xu C, Zhang F, Zhu C, Wu J, Chen K, Huang M, Wu Y, Zhang Y, Zheng W, Pan X, Chen B, Lin A, Tam J, van Dam R, Lai D, Chia K, Zhou L, Too H, Yu H, Mao W, Su D. Development of a serum miRNA panel for detection of early stage non-small cell lung cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 25036-25042. PMID: 32943537, PMCID: PMC7547174, DOI: 10.1073/pnas.2006212117.Peer-Reviewed Original ResearchConceptsNonsmall cell lung cancerCell lung cancerMinimally invasive testArea under curveLung cancerInvasive testingEarly stage NSCLCEarly stage non-small cell lung cancerNonsmall cell lung cancer casesNonsmall cell lung cancer detectionStage non-small cell lung cancerStage nonsmall cell lung cancerSerum miRNA panelsNon-small cell lung cancerSmoking statusStage I NSCLCIndependent of smoking statusImprove patient survivalEarly detectionEarly detection of lung cancerUnmet clinical needDetection of lung cancerCase-control cohortMiRNA panelNSCLC cases
1995
Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy.
Yu H, Diamandis E, Prestigiacomo A, Stamey T. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clinical Chemistry 1995, 41: 430-434. PMID: 7533672, DOI: 10.1093/clinchem/41.3.430.Peer-Reviewed Original ResearchConceptsTumor-doubling timeProstate-specific antigenProstate cancer relapseRelapse-free periodRadical prostatectomyPSA assaysCancer relapseUltrasensitive prostate specific antigenProstate cancer patientsUltrasensitive assayExponential tumor growthPSA changeCancer patientsPatientsProstatectomyTumor growthEarly detectionRelapseAntigenAssaysBasis of criteriaDaysCystoprostatectomyPostsurgerySurgery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply